2025-10-30 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the information you provided, presented in an English report format with numerical data and concise analysis.

## TransMedics Group Inc. (TMDX) Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) technology for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 237.85%
*   **VOO (S&P 500) Cumulative Return:** 79.28%
*   **Absolute Divergence (Current):** 126.6
*   **Relative Divergence (Current):** 62.5

**Analysis:** TMDX has significantly outperformed the S&P 500.  The current divergence is 126.6 percentage points, placing it in the upper half of its historical divergence range relative to the S&P 500. This indicates very strong relative performance.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD  | Alpha  | Beta | Cap(B) |
|------------|--------|------|--------|------|--------|
| 2019-2021  | -18.0% | 83.5% | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%  | 83.5% | 95.0%  | 0.0  | 2.1    |
| 2021-2023  | 65.0%  | 80.5% | 64.0%  | 0.1  | 2.7    |
| 2022-2024  | 130.0% | 85.5% | 109.0% | 0.1  | 2.1    |
| 2023-2025  | 159.0% | 85.5% | 90.0%  | 0.3  | 4.6    |

**Analysis:**

*   **CAGR:** Shows very strong growth in recent periods (2020-2025).
*   **MDD:** Consistently high Maximum Drawdown indicates significant price volatility and risk.
*   **Alpha:**  Very high Alpha values in recent periods (2020-2025) demonstrate substantial outperformance relative to its benchmark (S&P 500).
*   **Beta:** Low Beta values suggest that TMDX's returns are not highly correlated with the overall market. This is unusual for individual stocks but can indicate unique drivers of performance. Increasing values from 2019(0.0) to 2025(0.3)
*    **Cap(B):** Company size is increasing

### 2. Recent Price Action

*   **Current Price:** 134.89
*   **Last Market Close:** Price: 135.14, Previous Close: 129.71, Change: 4.19
*   **5-day Moving Average:** 129.26
*   **20-day Moving Average:** 118.23
*   **60-day Moving Average:** 117.69

**Analysis:** The stock is trading above all its moving averages, indicating a strong uptrend. The significant price increase in the last market session (change of 4.19) suggests strong positive momentum. This recent jump may be related to the positive news events noted below.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 70.77 (Approaching overbought territory)
*   **PPO:** 1.94
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (8 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** +6.1 (Short-term Increase)
*   **Expected Return:** 47.9% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates a favorable investment environment for TMDX.
*   **RSI:** Suggests the stock may be approaching overbought conditions and could be due for a pullback, but momentum can persist in strong uptrends.
*   **PPO:** Positive PPO value indicates that the short-term moving average is above the long-term moving average, confirming the uptrend.
*   **Hybrid Signal:** Aggressively bullish signal recommending full investment.
*   **Recent Relative Divergence Change:** Reinforces the short-term upward momentum.
*   **Expected Return:** A very high expected return suggests strong confidence in TMDX's future performance relative to the overall market.

### 4. Recent News & Significant Events

*   **[2025-10-28] Heart Transplant Play Nears Buy Point:** Positive coverage from Investor's Business Daily.
*   **[2025-10-27] 3 Stocks Estimated To Be Undervalued By Up To 48.5%:** Potential undervaluation highlighted by Simply Wall St.
*   **[2025-10-23] Needham Upgrades TransMedics Group to Buy:** A significant analyst upgrade driving positive sentiment.
*   **[2025-10-23] LendingClub upgraded, Enphase Energy downgraded: Wall Street's top analyst calls:** industry comparison.
*   **[2025-10-23] Needham Sets $148 Price Target:** Provides a specific price target suggesting further upside.
*   **[2025-10-15] TransMedics to Report Third Quarter 2025 Financial Results:** Upcoming earnings announcement could be a catalyst.

**Analysis:** Recent news is overwhelmingly positive, including analyst upgrades, price target increases, and recognition of potential undervaluation. This news flow likely contributes to the recent price surge.

#### 4-2 Analyst Opinions

*   **Consensus:** Buy (1.67 on a 1-5 scale)
*   **Target Price (Avg/High/Low):** 141.64 / 170.00 / 114.00

**Analysis:** The analyst consensus is bullish, with an average price target suggesting further upside potential from the current price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has significantly exceeded EPS expectations in the most recent quarters, demonstrating strong earnings performance. The EPS exceeded expectation in the most recent quarters

### 6. Financial Information

| Quarter    | Revenue  | Profit Margin |
|------------|----------|---------------|
| 2025-06-30 | $0.16B   | 61.38%        |
| 2025-03-31 | $0.14B   | 61.47%        |
| 2024-12-31 | $0.12B   | 59.21%        |
| 2024-09-30 | $0.11B   | 55.94%        |
| 2024-06-30 | $0.11B   | 60.59%        |

| Quarter    | Equity   | ROE     |
|------------|----------|---------|
| 2025-06-30 | $0.32B   | 10.97%  |
| 2025-03-31 | $0.27B   | 9.64%   |
| 2024-12-31 | $0.23B   | 3.00%   |
| 2024-09-30 | $0.21B   | 2.01%   |
| 2024-06-30 | $0.19B   | 6.42%   |

**Analysis:**

*   **Revenue:**  Consistently increasing revenue quarter-over-quarter indicates strong sales growth.
*   **Profit Margin:** Very high and relatively stable profit margins suggest strong pricing power and efficient operations.
*   **Equity:** Increasing equity indicates a strengthening balance sheet.
*   **ROE:** Increasing ROE values suggest that TMDX is becoming more efficient at generating profits from its equity base.

### 7. Overall Summary & Conclusion

TransMedics Group Inc. (TMDX) exhibits strong performance characteristics:

*   **Outperformance:** Significant outperformance relative to the S&P 500.
*   **Growth:**  Strong revenue growth and increasing profitability.
*   **Positive Sentiment:** Positive analyst ratings, price target increases, and news flow.
*   **Technical Strength:**  Strong uptrend confirmed by moving averages and technical indicators.
*   **Earnings Surprises:** Consistent EPS beats.

**Conclusion:** Based on this analysis, TMDX appears to be a compelling investment opportunity. However, investors should be aware of the high volatility (MDD) and consider that the RSI is approaching overbought levels, which might lead to a short-term pullback. Upcoming earnings could be a key catalyst.
